Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.85B
Last updated: Nov 17, 2026 at 11:06 AM ET
Royalty Pharma Plc (RPRX) P/E Ratio & Valuation History
Royalty Pharma Plc (RPRX) trades at 12.9x trailing earnings and 11.7x sales. Its P/E of 12.9x is above its 5-year median of 8.2x. Its forward P/E is 34.4x. The median P/E across 7 similar companies is 30.0x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 62.5% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 12.9x |
| Forward P/E | 34.4x |
| Price to sales | 11.7x |
| Price to book | 4.5x |
| EV/EBITDA | 26.1x |
| PEG | 2.1 |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 12.9x | 8.2x | N/A |
| P/S | 11.7x | 7.3x | N/A |
| P/B | 4.5x | 2.7x | N/A |
Valuation History
Over the 6 year ends shown, its P/E ranged from 5.9x in 2023 to 13.7x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $38.64 | 8.0x | 7.4x | 3.3x |
| 2024 | $25.51 | 6.2x | 5.4x | 2.2x |
| 2023 | $28.09 | 5.9x | 5.7x | 2.6x |
| 2022 | $39.52 | 10.7x | 8.0x | 3.7x |
| 2021 | $39.85 | 13.7x | 7.7x | 4.2x |
| 2020 | $50.05 | 8.5x | 8.6x | 2.0x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RPRX
What is RPRX's forward P/E ratio?
Royalty Pharma Plc has a forward P/E ratio of 34.4x.
Is RPRX stock overvalued?
GNG's valuation label for RPRX is Fairly valued. Its P/E of 12.9x compares with a median of 30.0x across 7 similar companies.
What is RPRX's price to sales ratio?
Royalty Pharma Plc has a price to sales ratio of 11.7x.
What is Royalty Pharma Plc's average P/E ratio over 5 years?
Royalty Pharma Plc's median P/E over the last 5 years is 8.2x, from 60 month-end values through Oct 2026.
What is RPRX's PEG ratio?
Royalty Pharma Plc has a PEG ratio of 2.1.
RPRX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors